Arcutis Biotherapeutics, Inc. ARQT Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$11.3M+54.9% | —— | $7.41M+118% | -$15.89M+69.6% | -$25.06M+29.2% | ||
| $10.69M+9.3% | $10.06M+7.1% | $10.04M+2.6% | $10.49M-16.2% | $9.78M-2.5% | ||
| -$1.85M-115% | $31.11M+120% | $8.43M-49.3% | $21.27M+311% | $12.35M+8.8% | ||
| $14.58M+647% | $5K-98.1% | $5.89M— | $0-100% | $1.95M+1,627% | ||
| $5.61M+1,717% | —— | -$9.29M-243% | $554K+111% | $309K-68.9% | ||
| $20.77M+9,805% | $23.45M+77.9% | $5.57M-44.9% | $21.23M+134% | -$214K+35.5% | ||
| $11.73M+257% | $1.27M+1,817% | $1.76M-58.6% | -$4.3M-298% | $3.28M+159% | ||
| -$214K-296% | -$21K+94.8% | -$283K+42.2% | -$294K— | -$54K— | ||
| $562K-81.1% | $563K+79.9% | $562K-55.8% | $563K+182% | $2.98M+1,485% | ||
| $2.24M+107% | —— | -$1.75M+94.9% | —— | -$30.38M+3.9% | ||
| $0-100% | —— | —— | $78K— | $608K— | ||
| $62.15M+10.8% | $89.18M+413% | $68.54M+1,104% | $33.15M-73.6% | $56.11M-47.0% | ||
| $50.82M-25.8% | $55M-4.0% | $43.3M-52.2% | $60.65M-4.7% | $68.47M-11.4% | ||
| -$11.33M-196% | -$34.18M-198% | -$25.25M-130% | $17.42M+128% | $11.75M+141% | ||
| —— | $0-100% | $0-100% | $0-100% | $0-100% | ||
| $1.07M— | $0— | $0— | $0— | $0-100% | ||
| $1.07M+170% | $3.72M— | $1.48M+275% | $1.38M-5.2% | $395K-99.8% | ||
| -$119K-3,075% | $59K+125% | —— | $200K+869% | $4K+105% | ||
| -$8.15M+55.3% | -$4.21M+93.4% | -$25.62M-151% | $19.33M+118% | -$18.23M-118% | ||
| $2.91M+13.2% | $2.54M-14.1% | $2.62M-57.9% | $2.6M-60.1% | $2.57M-60.6% | ||
| $182K-78.8% | $0-100% | $551K-67.4% | $695K-70.9% | $859K-50.2% | ||
| $562K-81.1% | $563K+79.9% | $562K-55.8% | $563K+182% | $2.98M+1,485% | ||
| -$137K+31.5% | -$126K+33.0% | -$150K+18.9% | -$204K-12.1% | -$200K-11.1% | ||
| $11.73M+257% | $1.27M+1,817% | $1.76M-58.6% | -$4.3M-298% | $3.28M+159% | ||
| -$214K-296% | -$21K+94.8% | -$283K+42.2% | -$294K— | -$54K— | ||
| $461K+11.1% | $461K-82.2% | $449K-43.9% | $431K-57.1% | $415K-58.7% | ||
| $50.82M-25.8% | —— | —— | —— | $68.47M-5.2% | ||
| —— | $0— | $0— | $0— | $0— | ||
| $158K— | —— | —— | —— | $0— | ||
| -$119K-3,075% | $59K+125% | —— | $200K+869% | $4K+105% | ||
| $0-100% | —— | —— | —— | $10M— | ||
| $2.24M+107% | —— | -$1.75M+95.0% | —— | -$30.99M+1.9% | ||
| $2.24M+107% | —— | -$1.75M+95.0% | —— | -$30.99M+1.9% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Arcutis Biotherapeutics, Inc. generate?
- Arcutis Biotherapeutics, Inc. (ARQT) generated -$30.6M in operating cash flow over the trailing twelve months.
- What is Arcutis Biotherapeutics, Inc.'s free cash flow?
- After $686.0K of capital expenditures, Arcutis Biotherapeutics, Inc.'s free cash flow was -$31.3M over the trailing twelve months, up 81.4% year over year.
- Where does Arcutis Biotherapeutics, Inc.'s cash flow data come from?
- Every line is extracted from Arcutis Biotherapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
